Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by 9 Meters Biopharma

9 Meters Biopharma to Participate in the William Blair Biotech Focus Conference 2022
From 9 Meters Biopharma
Via AccessWire
Exposures Product Safety
Tickers NMTR
9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome
From 9 Meters Biopharma
Via AccessWire
Exposures Product Safety
Tickers NMTR
9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation
From 9 Meters Biopharma
Via AccessWire
Exposures Product Safety
Tickers NMTR
9 Meters Biopharma to Participate in the 2022 BIO International Convention
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma to Exhibit at Digestive Disease Week 2022
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma Presents Preclinical Data at the 2022 American Thoracic Society International Conference on the Use of Larazotide in Idiopathic Pulmonary Fibrosis
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2022
From 9 Meters Biopharma
Via AccessWire
Exposures Product Safety
Tickers NMTR
9 Meters Biopharma to Present at the H.C. Wainwright Global Investment Conference and the LifeSci Partners Immunology & Inflammation Symposium
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma and Celiac.com Announce Collaboration to Support Clinical Trial Enrollment in 9 Meter's Phase 3 Study for Celiac Disease
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma Announces Allowance of Patent for Anti-GIP Monoclonal Antibody NM-136 for the Treatment of Serious Metabolic Conditions
From 9 Meters Biopharma
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers NMTR
9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2021
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma to Present at the Maxim Group 2022 Virtual Growth Conference
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma to Present at the Oppenheimer 32nd Annual Healthcare Conference
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma Announces a Collaboration with NYU Langone Health Investigating NM-102 as a Potential Treatment for an Autoimmune Disorder
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and Larazotide for Celiac Disease
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma Announces Publication of Data on Larazotide for the Treatment of Multisystem Inflammatory Syndrome in Children (MIS-C)
From 9 Meters Biopharma
Via AccessWire
Exposures COVID-19
Tickers NMTR
9 Meters Biopharma to Present at the 2022 BIO CEO & Investor Conference
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma Announces Allowance of Patent for NM-102 in Combination with Immune Checkpoint Inhibitors
From 9 Meters Biopharma
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers NMTR
9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma, Inc. to Participate in the following Virtual January Investor Conferences
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma Appoints Sarah Liu as Chief Commercial Officer and Al Medwar as Senior Vice President of Investor Relations & Corporate Communications
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma, Inc. Awards Unrestricted Educational Grant Funding to Carol Rees Parrish, M.S., RDN, for Short Bowel Syndrome Education
From 9 Meters Biopharma
Via AccessWire
Tickers NMTR
9 Meters Biopharma Provides Business Update and Reports Financial Results for the Third Quarter 2021
From 9 Meters Biopharma
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
Tickers NMTR
9 Meters Biopharma, Inc. Announces Immuno-Oncology Collaboration with Gustave Roussy for NM-102, a Gut Microbiome Modulator
From 9 Meters Biopharma
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
Tickers NMTR
9 Meters Biopharma, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
Tickers NMTR
9 Meters Biopharma, Inc. Presents Pharmacokinetic Data from Phase 1b/2a Study with Vurolenatide, Currently in Phase 2 for Short Bowel Syndrome, at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
Tickers NMTR
9 Meters Biopharma, Inc. to Present Data on Therapeutic Candidate in Short Bowel Syndrome at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
Tickers NMTR
9 Meters Biopharma, Inc. Appoints Samantha Ventimiglia to Board of Directors
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
Tickers NMTR
9 Meters Biopharma, Inc. Announces Partnership with Non-Profit Gluten-Free Food Pantry Organization Mend Hunger
From 9 Meters Biopharma
Via AccessWire
Topics Hacking Regulatory Compliance
Exposures COVID-19 Information Security Legal
Tickers NMTR
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.